GPCR Key Statistics, Chart & Performance
The current stock price of GPCR is 34.57 USD. In the past month the price increased by 3.75%. In the past year, price increased by 3.66%.
GPCR Latest News, Press Relases and Analysis
GPCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.11 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.73B | ||
| MRK | MERCK & CO. INC. | 11.56 | 252.74B | ||
| PFE | PFIZER INC | 7.9 | 143.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.12B | ||
| ZTS | ZOETIS INC | 20.07 | 56.08B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.56 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.66 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.51B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.37B |
Related stock screener links
About GPCR
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 199 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Company Info
STRUCTURE THERAPEUTICS INC
601 Gateway Blvd Suite 900
South San Francisco CALIFORNIA US
Employees: 199
Phone: 16504571978
STRUCTURE THERAPEUTICS INC / GPCR FAQ
What does STRUCTURE THERAPEUTICS INC do?
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 199 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Can you provide the latest stock price for STRUCTURE THERAPEUTICS INC?
The current stock price of GPCR is 34.57 USD. The price decreased by -3.46% in the last trading session.
Does STRUCTURE THERAPEUTICS INC pay dividends?
GPCR does not pay a dividend.
What is the ChartMill rating of STRUCTURE THERAPEUTICS INC stock?
GPCR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is GPCR stock listed?
GPCR stock is listed on the Nasdaq exchange.
What is the Short Interest ratio of STRUCTURE THERAPEUTICS INC (GPCR) stock?
The outstanding short interest for STRUCTURE THERAPEUTICS INC (GPCR) is 29.52% of its float.
GPCR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to GPCR. When comparing the yearly performance of all stocks, GPCR is one of the better performing stocks in the market, outperforming 89.98% of all stocks.
GPCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GPCR. GPCR has a great financial health rating, but its profitability evaluates not so good.
GPCR Financial Highlights
Over the last trailing twelve months GPCR reported a non-GAAP Earnings per Share(EPS) of -2.95. The EPS decreased by -48.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.32% | ||
| ROE | -27.36% | ||
| Debt/Equity | 0 |
GPCR Forecast & Estimates
21 analysts have analysed GPCR and the average price target is 77.37 USD. This implies a price increase of 123.82% is expected in the next year compared to the current price of 34.57.